About Insulin gene enhancer protein ISL-1
Insulin gene enhancer protein ISL-1 (ISL1) is a protein
from Homo sapiens identified by UniProt accession
P61371, 349 residues long.
MolForge cross-references it against 0 known binders and
285 disease associations.
Target properties
| Protein name | Insulin gene enhancer protein ISL-1 |
|---|
| UniProt accession | P61371 |
|---|
| Gene | ISL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 349 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (285)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- heel bone mineral density · score 0.46
- body mass index · score 0.39
- systolic blood pressure · score 0.38
- smoking status measurement · score 0.37
- body fat percentage · score 0.37
- lean body mass · score 0.35
- bone quantitative ultrasound measurement · score 0.34
- fat body mass · score 0.33
- body height · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P61371-F1 | alphafold | PREDICTED | 71.86 | — |
Amino-acid sequence (349 residues)
MGDMGDPPKK KRLISLCVGC GNQIHDQYIL RVSPDLEWHA ACLKCAECNQ YLDESCTCFV RDGKTYCKRD YIRLYGIKCA KCSIGFSKND FVMRARSKVY HIECFRCVAC SRQLIPGDEF ALREDGLFCR ADHDVVERAS LGAGDPLSPL HPARPLQMAA EPISARQPAL RPHVHKQPEK TTRVRTVLNE KQLHTLRTCY AANPRPDALM KEQLVEMTGL SPRVIRVWFQ NKRCKDKKRS IMMKQLQQQQ PNDKTNIQGM TGTPMVAASP ERHDGGLQAN PVEVQSYQPP WKVLSDFALQ SDIDQPAFQQ LVNFSEGGPG SNSTGSEVAS MSSQLPDTPN SMVASPIEA
Explore Insulin gene enhancer protein ISL-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets